Trimethylamine N-oxide as a key microbial mediator in the progression of diabetic kidney disease

Table 4 Central experimental insights defining the fibrotic role of trimethylamine-N-oxide[1,9,10,15,17]

Experimental component	Key observation	Interpretation
Microbial profiling	Increase in TMA-producing taxa in diabetic animals	Dysbiosis acts as the initiating metabolic trigger
Plasma TMAO levels	Progressive rise during disease evolution	Represents an early and persistent metabolic signature
Microbiota transplantation	Non-diabetic recipients develop renal injury and fibrosis	Demonstrates microbiota-mediated transmission of pathogenic signals
Fibrotic markers	Upregulation of TGF-β1, Smad2/3, and α-SMA	Indicates direct activation of canonical profibrotic pathways
Inhibition of TMA formation	Reversal of structural and biochemical injury	Confirms causal and therapeutically reversible role of the TMAO-driven fibrotic pathway

TMAO: Trimethylamine-N-oxide; α-SMA: Alpha-smooth muscle actin; TGF-β: Transforming growth factor-beta.